Connecting Innovation Across Continents
In one of the most complex mandates in our firm's history, Crossover Consulting advised on the EUR 180M acquisition of a German biotechnology company by a Tokyo-listed HealthTech corporation. The transaction required navigating three legal jurisdictions, managing cultural sensitivities between Japanese and German corporate practices, and coordinating with regulatory authorities in both the EU and Japan.
The German target company, based in the Munich biotech cluster, had developed a breakthrough diagnostic platform with applications in oncology and rare diseases. With 14 granted patents and a Phase II clinical pipeline, the company represented a highly attractive acquisition target. However, the founding team and their European investors were cautious about surrendering control to a foreign acquirer and needed assurance that the company's R&D culture and scientific independence would be preserved.
Crossover Consulting was uniquely positioned to bridge this gap. Our deep understanding of both German Mittelstand values and Asian corporate governance practices allowed us to craft a deal structure that protected the founders' interests while delivering the strategic objectives sought by the Japanese buyer. We proposed an innovative earn-out mechanism tied to clinical milestones, preserving upside for the founding team while de-risking the acquisition for the buyer.
Navigating Regulatory Complexity
The transaction required foreign investment screening under Germany's amended AWV (Aussenwirtschaftsverordnung), given the healthcare sector's classification as critical infrastructure. Our regulatory affairs team coordinated closely with the German Federal Ministry for Economic Affairs and Climate Action to secure timely approval. Simultaneously, we managed the Japanese FEFTA notification requirements and coordinated with the buyer's internal compliance teams.
The due diligence process involved evaluating the target's IP portfolio across multiple patent jurisdictions, assessing the clinical pipeline's probability-weighted NPV, reviewing European regulatory submissions, and analyzing the implications of recent EU MDR (Medical Device Regulation) changes on the company's product roadmap.
A Transaction Built on Trust
The deal closed in 14 months from initial mandate to final signing, a remarkable timeline for a transaction of this complexity. The acquisition has since been recognized as a benchmark for cross-border healthcare M&A, with the combined entity launching three new diagnostic products and expanding its European clinical trials program. All 120 employees at the German site were retained, and the Munich facility was designated as the global center of excellence for diagnostics R&D.
Our Approach
Strategic Alignment
Identified common ground between Japanese buyer's global diagnostics strategy and German target's innovation pipeline. Developed a shared vision that addressed both parties' priorities.
Deal Structuring
Designed innovative earn-out mechanism tied to clinical milestones, balancing risk and reward across cultural expectations and corporate governance frameworks.
Regulatory Navigation
Managed foreign investment screening in Germany, FEFTA notifications in Japan, and EU healthcare regulatory requirements simultaneously.
Integration Planning
Developed a 100-day integration plan preserving the target's R&D culture while leveraging the buyer's global commercial infrastructure and distribution networks.